Liquid biopsy in tissue-born lymphomas

In the era of personalised medicine, genetic information is critical to directing therapeutic options, aiding risk stratification and disease monitoring of lymphomas. Liquid biopsy is a novel noninvasive, real-time and tumour-specific technique, reliably reflecting the comprehensive tumour genetic p...

Full description

Saved in:
Bibliographic Details
Published in:Swiss medical weekly 2019-01, Vol.149 (304), p.w14709-w14709
Main Authors: Spina, Valeria, Rossi, Davide
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - blood
cfDNA
genotyping
Genotyping Techniques
Hodgkin Disease - blood
Hodgkin Disease - genetics
Hodgkin Disease - pathology
Humans
liquid biopsy
Liquid Biopsy - methods
lymphoma
Lymphoma, Large B-Cell, Diffuse - blood
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - pathology
minimal residual disease
Neoplasm Recurrence, Local - blood
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Neoplasm, Residual - blood
Neoplasm, Residual - genetics
next generation sequencing
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the era of personalised medicine, genetic information is critical to directing therapeutic options, aiding risk stratification and disease monitoring of lymphomas. Liquid biopsy is a novel noninvasive, real-time and tumour-specific technique, reliably reflecting the comprehensive tumour genetic profile, and thus holds great promise for the genetic assessment, response monitoring and relapse detection of lymphomas. Standard methods for disease response assessment in patients with lymphoma, including positron emission tomography, are imperfect. In other haematological malignancies, particularly leukaemias, the ability to detect minimal residual disease (MRD) is increasingly influencing treatment paradigms. However, in some subtypes of lymphoma, such as diffuse large B-cell lymphoma and classic Hodgkin's lymphoma, the application of MRD assessment techniques such as flow cytometry or polymerase chain reaction-based methods has been challenged by the absence of circulating disease. The review summarises the applications of liquid biopsy in the assessment of tumour burden and response to therapy, noninvasive genomic profiling, and monitoring of clonal dynamics in patients with diffuse large B-cell lymphoma and classic Hodgkin's lymphoma.
ISSN:1424-3997
1424-3997
DOI:10.4414/smw.2019.14709